Real-world use of tafasitamab for relapsed or refractory diffuse large B-cell lymphoma among racial and ethnic minorities in the United States.
- DOI
- 10.1093/oncolo/oyag357
- Published
- 2026 Sep 12
- Container
- The oncologist
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/oncolo/oyag357,
title = {Real-world use of tafasitamab for relapsed or refractory diffuse large B-cell lymphoma among racial and ethnic minorities in the United States.},
author = {Epperla N and Nastoupil LJ and Feinberg B and Galvin J and Pathak P and Amoloja T and Gentile D and Asgarisabet P and Saverno K},
year = {2026},
journal = {The oncologist},
doi = {10.1093/oncolo/oyag357},
url = {https://doi.org/10.1093/oncolo/oyag357}
}RIS
TY - JOUR TI - Real-world use of tafasitamab for relapsed or refractory diffuse large B-cell lymphoma among racial and ethnic minorities in the United States. AU - Epperla N AU - Nastoupil LJ AU - Feinberg B AU - Galvin J AU - Pathak P AU - Amoloja T AU - Gentile D AU - Asgarisabet P AU - Saverno K PY - 2026 JO - The oncologist DO - 10.1093/oncolo/oyag357 UR - https://doi.org/10.1093/oncolo/oyag357 ER -
APA
N, E., LJ, N., B, F., J, G., P, P., T, A., D, G., P, A., & K, S. (2026). Real-world use of tafasitamab for relapsed or refractory diffuse large B-cell lymphoma among racial and ethnic minorities in the United States.. The oncologist. https://doi.org/10.1093/oncolo/oyag357
Source records
- pubmed · retrieved 2026-09-26T09:10:28.848Z
- europe-pmc · retrieved 2026-09-26T09:10:28.827Z